Search

Your search keyword '"Kostakoglu, Lale"' showing total 658 results
Start Over Author "Kostakoglu, Lale"
658 results on '"Kostakoglu, Lale"'

1. Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)

Author

Allaf, Mohamad, Andriole, Gerald, Avery, Ryan J., Avril, Norbert, Barker, Helen, Belkoff, Laurence, Budäus, Lars, Cher, Michael L., Chisholm, Diane, Covington, Matthew F., Cox, Ian, Ferrandino, Michael, Fleming, Mark T., Franceschi, Dinko, Gardiner, Peter, Gartrell, Benjamin, Gauden, David, Hasa, Ergela, Hermsen, Rick, Horn, Thomas, Iranpour, Pooya, Jacene, Heather, Jayaratna, Isuru, Joshi, Shreyas S., Kay, Matthew, Kostakoglu, Lale, Kuo, Phillip, Lavely, William, Lokuta, Mary, Lowentritt, Benjamin, Miller, Matthew P., Nix, Jeffrey W., Ogan, Kenneth, Penny, Ross, Piert, Morand, Purysko, Andrei, Ravizzini, Gregory, Saltzstein, Daniel, Savir-Baruch, Bital, Siegel, Barry A., Steuber, Thomas, Twardowski, Przemyslaw, Uchio, Edward, Ulaner, Gary A., Wixom, Jenna M., Yoo, Don, Zukotynski, Katherine, Surasi, Devaki Shilpa, Eiber, Matthias, Maurer, Tobias, Preston, Mark A., Helfand, Brian T., Josephson, David, Tewari, Ashutosh K., Somford, Diederik M., Rais-Bahrami, Soroush, Koontz, Bridget F., Bostrom, Peter J., Chau, Albert, Davis, Phillip, Schuster, David M., and Chapin, Brian F.

Published
2023
Full Text
View/download PDF

2. A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma

Author

Thieblemont, Catherine, Chartier, Loic, Dührsen, Ulrich, Vitolo, Umberto, Barrington, Sally F., Zaucha, Jan M., Vercellino, Laetitia, Gomes Silva, Maria, Patrocinio-Carvalho, Ines, Decazes, Pierre, Viailly, Pierre-Julien, Tilly, Herve, Berriolo-Riedinger, Alina, Casasnovas, Oliver, Hüttmann, Andreas, Ilyas, Hajira, Mikhaeel, N. George, Dunn, Joel, Cottereau, Anne-Ségolène, Schmitz, Christine, Kostakoglu, Lale, Paulson, Joseph N., Nielsen, Tina, and Meignan, Michael

Published
2022
Full Text
View/download PDF

4. Automated Lugano Metabolic Response Assessment in 18F-Fluorodeoxyglucose–Avid Non-Hodgkin Lymphoma With Deep Learning on 18F-Fluorodeoxyglucose–Positron Emission Tomography

Author

Jemaa, Skander, primary, Ounadjela, Souhila, additional, Wang, Xiaoyong, additional, El-Galaly, Tarec C., additional, Kostakoglu, Lale, additional, Knapp, Andrea, additional, Ku, Grace, additional, Musick, Lisa, additional, Sahin, Denis, additional, Wei, Michael C., additional, Yin, Shen, additional, Bengtsson, Thomas, additional, De Crespigny, Alex, additional, and Carano, Richard A.D., additional

Published
2024
Full Text
View/download PDF

5. ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy

Author

Ratai, Eva-Maria, Zhang, Zheng, Fink, James, Muzi, Mark, Hanna, Lucy, Greco, Erin, Richards, Todd, Kim, Daniel, Andronesi, Ovidiu C, Mintz, Akiva, Kostakoglu, Lale, Prah, Melissa, Ellingson, Benjamin, Schmainda, Kathleen, Sorensen, Gregory, Barboriak, Daniel, Mankoff, David, Gerstner, Elizabeth R, and group, on behalf of the ACRIN 6684 trial

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Cancer, Orphan Drug, Biomedical Imaging, Brain Cancer, Clinical Research, Neurosciences, Rare Diseases, Brain Disorders, Precision Medicine, Bioengineering, 4.2 Evaluation of markers and technologies, Aged, Brain, Brain Neoplasms, Female, Glioblastoma, Humans, Imaging, Three-Dimensional, Magnetic Resonance Imaging, Male, Middle Aged, Misonidazole, Positron-Emission Tomography, Prognosis, Proton Magnetic Resonance Spectroscopy, ROC Curve, Radiopharmaceuticals, Tumor Hypoxia, ACRIN 6684 trial group, General Science & Technology
Abstract

A multi-center imaging trial by the American College of Radiology Imaging Network (ACRIN) "A Multicenter, phase II assessment of tumor hypoxia in glioblastoma using 18F Fluoromisonidazole (FMISO) with PET and MRI (ACRIN 6684)", was conducted to assess hypoxia in patients with glioblastoma (GBM). The aims of this study were to support the role of proton magnetic resonance spectroscopic imaging (1H MRSI) as a prognostic marker for brain tumor patients in multi-center clinical trials. Seventeen participants from four sites had analyzable 3D MRSI datasets acquired on Philips, GE or Siemens scanners at either 1.5T or 3T. MRSI data were analyzed using LCModel to quantify metabolites N-acetylaspartate (NAA), creatine (Cr), choline (Cho), and lactate (Lac). Receiver operating characteristic curves for NAA/Cho, Cho/Cr, lactate/Cr, and lactate/NAA were constructed for overall survival at 1-year (OS-1) and 6-month progression free survival (PFS-6). The OS-1 for the 17 evaluable patients was 59% (10/17). Receiver operating characteristic analyses found the NAA/Cho in tumor (AUC = 0.83, 95% CI: 0.61 to 1.00) and in peritumoral regions (AUC = 0.95, 95% CI 0.85 to 1.00) were predictive for survival at 1 year. PFS-6 was 65% (11/17). Neither NAA/Cho nor Cho/Cr was effective in predicting 6-month progression free survival. Lac/Cr in tumor was a significant negative predictor of PFS-6, indicating that higher lactate/Cr levels are associated with poorer outcome. (AUC = 0.79, 95% CI: 0.54 to 1.00). In conclusion, despite the small sample size in the setting of a multi-center trial comprising different vendors, field strengths, and varying levels of expertise at data acquisition, MRS markers NAA/Cho, Lac/Cr and Lac/NAA predicted overall survival at 1 year and 6-month progression free survival. This study validates that MRSI may be useful in evaluating the prognosis in glioblastoma and should be considered for incorporating into multi-center clinical trials.

Published
2018

6. Brain and blood biomarkers of tauopathy and neuronal injury in humans and rats with neurobehavioral syndromes following blast exposure

Author

Dickstein, Dara L., De Gasperi, Rita, Gama Sosa, Miguel A., Perez-Garcia, Georgina, Short, Jennifer A., Sosa, Heidi, Perez, Gissel M., Tschiffely, Anna E., Dams-O’Connor, Kristen, Pullman, Mariel Y., Knesaurek, Karin, Knutsen, Andrew, Pham, Dzung L., Soleimani, Lale, Jordan, Barry D., Gordon, Wayne A., Delman, Bradley N., Shumyatsky, Gleb, Shahim, Pashtun-Poh, DeKosky, Steven T., Stone, James R., Peskind, Elaine, Blennow, Kaj, Zetterberg, Henrik, Chance, Steven A., Torso, Mario, Kostakoglu, Lale, Sano, Mary, Hof, Patrick R., Ahlers, Stephen T., Gandy, Sam, and Elder, Gregory A.

Published
2021
Full Text
View/download PDF

8. PET in Lymphoma

Author

Ghesani, Nasrin, Gavane, Somali, Hafez, Anthony, Kostakoglu, Lale, Ahmadzadehfar, Hojjat, editor, Biersack, Hans-Jürgen, editor, Freeman, Leonard M., editor, and Zuckier, Lionel S., editor

Published
2020
Full Text
View/download PDF

10. 18F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE

Author

Adler, Lee P., Andriole, Gerald L., Belkoff, Laurence H., Burzon, Daniel, Chau, Albert, Dato, Paul, Duan, Fenghai, Farwell, Michael, Fogelson, Stephen, Gardiner, Peter, Hanna, Lucy, Hoffman, John M., Intenzo, Charles, Josephson, David, Kaminetsky, Jed, Kipper, Michael, Kostakoglu, Lale, Krynyckyi, Borys, Linder, Karen E., Mahmood, Umar, Marques, Helga, Mankoff, David, McConathy, Jonathan, Melnick, John, Miller, Matthew P., Oh, William, Philips, Shaile, Rose, Judith, Savir-Baruch, Bital, Schuster, David M., Siegel, Barry A., Stevens, Daniel J., Tewari, Ashutosh, Twardowski, Przemyslaw, Ward, Penelope, Wasserman, Martha, Weick, Sharon, (Michael) Yu, Jian Q., Solanki, Abhishek A., Liauw, Stanley L., Michalski, Jeff, Tward, Jonathan D., Vapiwala, Neha, and Teoh, Eugene J.

Published
2020
Full Text
View/download PDF

11. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial

Author

Schöder, Heiko, Polley, Mei-Yin C., Knopp, Michael V., Hall, Nathan, Kostakoglu, Lale, Zhang, Jun, Higley, Howard R., Kelloff, Gary, Liu, Heshan, Zelenetz, Andrew D., Cheson, Bruce D., Wagner-Johnston, Nina, Kahl, Brad S., Friedberg, Jonathan W., Hsi, Eric D., Leonard, John P., Schwartz, Lawrence H., Wilson, Wyndham H., and Bartlett, Nancy L.

Published
2020
Full Text
View/download PDF

14. ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI

Author

Gerstner, Elizabeth R, Group, for the ACRIN 6684 Trial, Zhang, Zheng, Fink, James R, Muzi, Mark, Hanna, Lucy, Greco, Erin, Prah, Melissa, Schmainda, Kathleen M, Mintz, Akiva, Kostakoglu, Lale, Eikman, Edward A, Ellingson, Benjamin M, Ratai, Eva-Maria, Sorensen, A Gregory, Barboriak, Daniel P, and Mankoff, David A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Rare Diseases, Biomedical Imaging, Neurosciences, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Adult, Aged, Biomarkers, Brain Neoplasms, Disease-Free Survival, Female, Glioblastoma, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Misonidazole, Neovascularization, Pathologic, Positron-Emission Tomography, Prospective Studies, Radiopharmaceuticals, Tumor Hypoxia, ACRIN 6684 Trial Group, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeStructural and functional alterations in tumor vasculature are thought to contribute to tumor hypoxia which is a primary driver of malignancy through its negative impact on the efficacy of radiation, immune surveillance, apoptosis, genomic stability, and accelerated angiogenesis. We performed a prospective, multicenter study to test the hypothesis that abnormal tumor vasculature and hypoxia, as measured with MRI and PET, will negatively impact survival in patients with newly diagnosed glioblastoma.Experimental designPrior to the start of chemoradiation, patients with glioblastoma underwent MRI scans that included dynamic contrast enhanced and dynamic susceptibility contrast perfusion sequences to quantitate tumor cerebral blood volume/flow (CBV/CBF) and vascular permeability (ktrans) as well as 18F-Fluoromisonidazole (18F-FMISO) PET to quantitate tumor hypoxia. ROC analysis and Cox regression models were used to determine the association of imaging variables with progression-free and overall survival.ResultsFifty patients were enrolled of which 42 had evaluable imaging data. Higher pretreatment 18F-FMISO SUVpeak (P = 0.048), mean ktrans (P = 0.024), and median ktrans (P = 0.045) were significantly associated with shorter overall survival. Higher pretreatment median ktrans (P = 0.021), normalized RCBV (P = 0.0096), and nCBF (P = 0.038) were significantly associated with shorter progression-free survival. SUVpeak [AUC = 0.75; 95% confidence interval (CI), 0.59-0.91], nRCBV (AUC = 0.72; 95% CI, 0.56-0.89), and nCBF (AUC = 0.72; 95% CI, 0.56-0.89) were predictive of survival at 1 year.ConclusionsIncreased tumor perfusion, vascular volume, vascular permeability, and hypoxia are negative prognostic markers in newly diagnosed patients with gioblastoma, and these important physiologic markers can be measured safely and reliably using MRI and 18F-FMISO PET. Clin Cancer Res; 22(20); 5079-86. ©2016 AACR.

Published
2016

21. A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials

Author

Kostakoglu, Lale, primary, Martelli, Maurizio, additional, Sehn, Laurie H., additional, Davies, Andrew, additional, Trněný, Marek, additional, Herold, Michael, additional, Vitolo, Umberto, additional, Hiddemann, Wolfgang, additional, Trotman, Judith, additional, Knapp, Andrea, additional, Mattiello, Federico, additional, Nielsen, Tina G., additional, Sahin, Deniz, additional, Sellam, Gila, additional, Ward, Carol, additional, and Younes, Anas, additional

Published
2023
Full Text
View/download PDF

24. P1244: AN AUTOMATED QUANTIFICATION ALGORITHM FOR EVALUATING TOTAL METABOLIC TUMOR VOLUME IN PATIENTS WITH FDG-AVID LYMPHOMAS USING A DEEP LEARNING MODEL

Author

Xu, Tao, primary, Jemaa, Skander, additional, Kumar, Manas, additional, Balasubramanian, Sandhya, additional, Shamas-Din, Aisha, additional, Lyalina, Svetlana, additional, Ounadjela, Souhila, additional, Malik, Bilal, additional, Lee, Joe, additional, Figueroa Morales, Salvador, additional, Nielsen, Tina, additional, Ad Carano, Rick, additional, Kostakoglu, Lale, additional, and Capra, William, additional

Published
2023
Full Text
View/download PDF

26. Supplemental Tables 1-2 from ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI

Author

Gerstner, Elizabeth R., primary, Zhang, Zheng, primary, Fink, James R., primary, Muzi, Mark, primary, Hanna, Lucy, primary, Greco, Erin, primary, Prah, Melissa, primary, Schmainda, Kathleen M., primary, Mintz, Akiva, primary, Kostakoglu, Lale, primary, Eikman, Edward A., primary, Ellingson, Benjamin M., primary, Ratai, Eva-Maria, primary, Sorensen, A. Gregory, primary, Barboriak, Daniel P., primary, and Mankoff, David A., primary

Published
2023
Full Text
View/download PDF

29. Positron Emission Tomography–Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance)

Author

LaCasce, Ann S., primary, Dockter, Travis, additional, Ruppert, Amy S., additional, Kostakoglu, Lale, additional, Schöder, Heiko, additional, Hsi, Eric, additional, Bogart, Jeffrey, additional, Cheson, Bruce, additional, Wagner-Johnston, Nina, additional, Abramson, Jeremy, additional, Blum, Kristie, additional, Leonard, John P., additional, and Bartlett, Nancy L., additional

Published
2023
Full Text
View/download PDF

35. Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411

Author

Smith, Mitchell R, primary, Jegede, Opeyemi, additional, Martin, Peter, additional, Till, Brian G., additional, Parekh, Samir, additional, Yang, David T., additional, Kostakoglu, Lale, additional, Casulo, Carla, additional, Bartlett, Nancy, additional, Caimi, Paolo F, additional, Al Baghdadi, Tareq, additional, Maddocks, Kami J., additional, Romer, Mark D., additional, Inwards, David J., additional, Lerner, Rachel E., additional, Wagner, Lynne I., additional, Little, Richard, additional, Friedberg, Jonathan W., additional, Leonard, John P., additional, and Kahl, Brad S., additional

Published
2022
Full Text
View/download PDF

36. FLIPI-3: A New PET-Based Prognostic Index for Follicular Lymphoma Based on Results from a Validation Study with the ECOG-ACRIN E2408 Cohort

Author

St-Pierre, Frederique, primary, Broski, Stephen, additional, Sun, Zequn, additional, Kocherginsky, Masha, additional, Quon, Andrew, additional, Baratto, Lucia, additional, Savas, Hatice, additional, Kostakoglu, Lale, additional, Winter, Jane N., additional, Witzig, Thomas E., additional, Kahl, Brad S., additional, Evens, Andrew Matthew, additional, and Gordon, Leo I., additional

Published
2022
Full Text
View/download PDF

42. PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design

Author

Broglio, Kristine, primary, Kostakoglu, Lale, additional, Ward, Carol, additional, Mattiello, Federico, additional, Sahin, Denis, additional, Nielsen, Tina, additional, McGlothlin, Anna, additional, Elliott, Corrine F., additional, Witzig, Thomas, additional, Sehn, Laurie H., additional, Trnĕný, Marek, additional, Vitolo, Umberto, additional, Martelli, Maurizio, additional, Foster, Margaret, additional, Wendelberger, Barbara, additional, Nowakowski, Grzegorz, additional, and Berry, Donald A., additional

Published
2022
Full Text
View/download PDF

44. FDG-PET for Early Response Assessment in Lymphomas: PART 2: Diffuse Large B-Cell Lymphoma, Use of Quantitative PET Evaluation

Author

Cheson, Bruce D. and Kostakoglu, Lale

Subjects
Diagnosis, Care and treatment, Patient outcomes, Hodgkin's disease -- Diagnosis -- Care and treatment, Early intervention -- Patient outcomes
Abstract

Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of B-cell non-Hodgkin lymphoma; it accounts for approximately 35% of B-cell non-Hodgkin lymphomas and 80% of aggressive lymphomas. [1] [...], In Part 1, we reviewed the role of interim positron emission tomography (PET)/CT scans in Hodgkin lymphoma. In advanced Hodgkin lymphoma, interim PET is a useful prognostic tool that can be used to implement risk-adapted therapy with potential benefits for both patients who have negative interim scans and those whose scans are positive. Interim PET/CT has not shown as encouraging results in diffuse large B-cell lymphoma (DLBCL), with the exception of germinal center B-cell DLBCL. Thus, quantitative methods of interpreting interim PET scans have been pursued in an effort to improve their predictive value. Early results using the change in maximal standardized uptake value between baseline and interim PET ([DELTA][SUV.sub.max]) to quantitatively interpret interim PET scans in DLBCL patients showed promise, but later results were contradictory. Thus, there is not firm evidence of a prognostic value for interim PET interpreted using either visual or [DELTA][SUV.sub.max]-based analysis in patients with DLBCL. Nor are there data to support altering treatment in DLBCL on the basis of an interim PET scan. More sophisticated methods of quantitative interpretation of interim PET, using metabolic tumor volume and tumor lesion glycolysis measurements, have been investigated in both Hodgkin lymphoma and DLBCL. Although to date studies of these approaches have been small and heterogeneous, they do provide some support for the potential of a PET-derived volumetric approach to discriminate between risk groups better than [DELTA][SUV.sub.max]; this remains to be proven in well-designed large-scale studies.

Published
2017

45. FDG-PET for Early Response Assessment in Lymphomas: PART 1: Hodgkin Lymphoma

Author

Cheson, Bruce D. and Kostakoglu, Lale

Subjects
Diagnosis, Care and treatment, Hodgkin's disease -- Diagnosis -- Care and treatment, Cancer research, Lymphomas, Cancer treatment, Positron emission tomography, Diagnostic imaging, Vincristine, Tumors, Non-Hodgkin's lymphomas, Retirement benefits, Tomography
Abstract

Introduction Hodgkin lymphoma is one of the true success stories of modern hematology/oncology. The cure rate in patients with limited-stage disease is around 95%, and 80% for those with advanced-stage [...], Interim positron emission tomography (PET)/CT has shown encouraging results when used as a prognostic tool early in the course of treatment of advanced Hodgkin lymphoma, allowing for a reduction in treatment for patients with favorable characteristics, while suggesting a benefit from changing therapy for those with a positive scan. For patients with limited disease, a negative scan allows for a decrease in treatment; however, the benefits for those patients whose scans are positive are less certain. Here we critically analyze the role of PET/CT in the early assessment of Hodgkin lymphoma. In Part 2, we will review the role of interim PET/CT in diffuse large B-cell lymphoma (DLBCL), and also explore the question of whether new approaches to quantitative assessment improve the prognostic value of interim PET scans in both Hodgkin lymphoma and DLBCL.

Published
2017

47. A prognostic model integrating PET‐derived metrics and image texture analyses with clinical risk factors from GOYA

Author

Kostakoglu, Lale, primary, Dalmasso, Federico, additional, Berchialla, Paola, additional, Pierce, Larry A., additional, Vitolo, Umberto, additional, Martelli, Maurizio, additional, Sehn, Laurie H., additional, Trněný, Marek, additional, Nielsen, Tina G., additional, Bolen, Christopher R., additional, Sahin, Deniz, additional, Lee, Calvin, additional, El‐Galaly, Tarec Christoffer, additional, Mattiello, Federico, additional, Kinahan, Paul E., additional, and Chauvie, Stephane, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results